What men should know about the US government’s latest move on testosterone therapy
The Department of Health and Human Services is seeking updates to testosterone replacement therapy labels. These changes follow a review of evidence regarding the safety and benefits of the treatments. The move aims to align labels with recent science and improve access to hormone drugs.
What changed
The government is specifically requesting label revisions based on a review of new data and evidence.
Live updates
-
US Government Requests Revisions to Testosterone Therapy Labels
confidence 90%The Department of Health and Human Services is seeking updates to testosterone replacement therapy labels. These changes follow a review of evidence regarding the safety and benefits of the treatments. The move aims to align labels with recent science and improve access to hormone drugs.
What's confirmed:
- The U.S. Department of Health and Human Services is requesting revisions to labels on testosterone replacement therapies for men.
- The request for label changes follows a review of data and evidence concerning the safety and benefits of the therapies.
- The government wants labels to reflect more recent science as part of a push to ease access to hormone drugs.
Still unconfirmed:
- Federal health officials are acting to address dropping testosterone levels and rising rates of suicide and chronic disease.
-
US Government Moves to Ease Testosterone Therapy Restrictions
confidence 90%The Department of Health and Human Services and the FDA are proposing updates to testosterone replacement therapy labels. These changes follow a review of safety and benefit data. The goal is to make these treatments more accessible for men.
What's confirmed:
- The Department of Health and Human Services is requesting revisions to testosterone replacement therapy labels.
- Proposed updates include revising warnings about prostate cancer risk.
- HHS plans to remove restrictions on therapy related to hypogonadism or enlarged prostate.
- An FDA panel recommended easing restrictions on testosterone replacement therapy.
- The FDA is encouraging product sponsors to explore a new indication for low libido in men with idiopathic hypogonadism.
Still unconfirmed:
- An FDA panel suggested removing the classification of these therapies as controlled substances.
- RFK Jr. is moving to lift warning labels on testosterone therapy.
- The Trump administration is seeking to roll back testosterone restrictions.